DcR2 Antikörper

Produktnummer ABIN1169231

Produktdetails anti-DcR2 Antikörper

Target: DcR2 (TNFRSF10D) (Tumor Necrosis Factor Receptor Superfamily, Member 10d, Decoy with Truncated Death Domain (TNFRSF10D))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser DcR2 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC), Immunoprecipitation (IP)

Spezifität: Recognizes human TRAIL-R4.

Kreuzreaktivität: Human

Kreuzreaktivität (Details): Does not cross-react with human TRAIL-R1, -R2 or -R3.

Aufreinigung: Purified from concentrated hybridoma tissue culture supernatant.

Reinheit: >95 % (SDS-PAGE)

Immunogen: Recombinant human TRAIL-R4 (DcR2).

Klon: HS402

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: In PBS containing 10 % glycerol and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Haltbarkeit: 12 months

Referenzen für anti-DcR2 Antikörper (ABIN1169231)

Hartwig, Montinaro, von Karstedt, Sevko, Surinova, Chakravarthy, Taraborrelli, Draber, Lafont, Arce Vargas, El-Bahrawy, Quezada, Walczak: "The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2." in: Molecular cell, Vol. 65, Issue 4, pp. 730-742.e5, (2017) (PubMed).

Secchiero, Melloni, Heikinheimo, Mannisto, Di Pietro, Iacone, Zauli: "TRAIL regulates normal erythroid maturation through an ERK-dependent pathway." in: Blood, Vol. 103, Issue 2, pp. 517-22, (2004) (PubMed).

Ganten, Haas, Sykora, Stahl, Sprick, Fas, Krueger, Weigand, Grosse-Wilde, Stremmel, Krammer, Walczak: "Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs." in: Cell death and differentiation, Vol. 11 Suppl 1, pp. S86-96, (2004) (PubMed).

Washburn, Weigand, Grosse-Wilde, Janke, Stahl, Rieser, Sprick, Schirrmacher, Walczak: "TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 4, pp. 1814-21, (2003) (PubMed).

Details zu DcR2

Target: DcR2 (TNFRSF10D) (Tumor Necrosis Factor Receptor Superfamily, Member 10d, Decoy with Truncated Death Domain (TNFRSF10D))

Andere Bezeichnung: TRAIL-R4 (TNFRSF10D Produkte)

Synonyme: TNFRSF10D antikoerper, CD264 antikoerper, DCR2 antikoerper, TRAIL-R4 antikoerper, TRAILR4 antikoerper, TRUNDD antikoerper, TNF receptor superfamily member 10d antikoerper, tumor necrosis factor receptor superfamily member 10D antikoerper, TNFRSF10D antikoerper, LOC716901 antikoerper

Hintergrund: TRAIL-R4 is a receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.

UniProt: Q9UBN6

Pathways: Apoptose